Cellectis S.A. SEC filings CLLS
Cellectis S.A. has 534 filings in SEC EDGAR's recent list, going back to Dec 19, 2014. Its latest annual report, Form 20-F, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 28, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 12, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 30, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 24, 2025 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 21, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Dec 5, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 16, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 13, 2023 | — |
| SC 13D | Ownership over 5% (active) | Nov 9, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 1, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 18, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 17, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 1, 2022 | — |
| SC 13G | Ownership over 5% (passive) | May 3, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Jan 12, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 12, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 8, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Nov 10, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 23, 2020 | — |
| 4 | Insider transaction | Oct 20, 2020 | Oct 16, 2020 |
| SC 13D | Ownership over 5% (active) | Aug 4, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 10, 2020 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2020 | — |
| SC 13D/A | Amended ownership over 5% (active) | Sep 23, 2019 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2019 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 15, 2018 | — |
| 4 | Insider transaction | Jun 15, 2018 | Jun 15, 2018 |
| SC 13D | Ownership over 5% (active) | May 29, 2018 | — |
| 4 | Insider transaction | May 21, 2018 | May 17, 2018 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2018 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2018 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2018 | — |
| 3 | Initial insider ownership | Jul 20, 2017 | Jul 19, 2017 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 15, 2017 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2017 | — |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2017 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 10, 2017 | — |
| SC 13G | Ownership over 5% (passive) | Feb 16, 2016 | — |
| SC 13G | Ownership over 5% (passive) | Feb 12, 2016 | — |
| SC 13G | Ownership over 5% (passive) | Feb 12, 2016 | — |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Paris, Lle-De-France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1627281
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.